Astria Therapeutics, Inc.
ATXSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How ATXS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
navenibart | Phase 3 | Hereditary Angioedema (HAE) | - | - |
STAR-0215 | Phase 2 | Hereditary Angioedema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Astria Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Astria Therapeutics, Inc.'s (ATXS) pipeline across Phase 3, Phase 2. Its lead program is navenibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Astria Therapeutics, Inc.'s next FDA catalyst?→
Astria Therapeutics, Inc.'s (ATXS) next tracked catalyst is a Phase 3 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATXS biotech catalysts?→
Add ATXS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Astria Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.